GlassScriptPhysician profile
Fatma A Radhi
NPI 1396848461
$2,652.59
in general payments reported to CMS, 2019-2025
31 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $1,129 · 2021: $248 · 2022: $65.89 · 2023: $195 · 2024: $19.76 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $359.71 | 2019-2021 | |
| Livanova USA, INC. | $225.09 | 2019-2022 | |
| Emd Serono, INC. | $223.48 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $157.38 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $138.93 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $117.82 | 2019-2025 | |
| Ucb, INC. | $116.02 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $107.57 | 2023 | Horizant |
| Amgen INC. | $103.43 | 2019-2021 | |
| Biogen, INC. | $98.19 | 2019-2021 | |
| Lilly USA, LLC | $96.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $94.12 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $89.87 | 2019-2020 | |
| Acorda Therapeutics, INC | $85.82 | 2019 | |
| Harmony Biosciences LLC | $83.86 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $82.93 | 2019-2020 | |
| Lundbeck LLC | $82.76 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $55.93 | 2020-2021 | |
| Abbvie INC. | $51.69 | 2022-2024 | |
| Adamas Pharmaceuticals, INC. | $42.38 | 2019-2020 | |
| Kyowa Kirin, INC. | $36.29 | 2020 | |
| Sk Life Science, INC. | $34.83 | 2020 | |
| Genentech USA, INC. | $29.72 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $27.89 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $20.32 | 2021 | |
| Upsher-Smith Laboratories LLC | $17.63 | 2020 | |
| Amneal Pharmaceuticals LLC | $16.67 | 2019 | |
| Neurocrine Biosciences, INC. | $14.88 | 2020 | |
| Allergan, INC. | $14.19 | 2020 | |
| Grt US Holding, INC. | $14.10 | 2020 | |
| Eisai INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatma Radhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.